Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1973 1
1982 1
1983 2
1984 1
1985 1
1986 1
1987 5
1988 5
1989 10
1990 11
1991 10
1992 15
1993 9
1994 5
1995 11
1996 11
1997 11
1998 8
1999 3
2000 11
2001 12
2002 9
2003 7
2004 8
2005 8
2006 7
2007 8
2008 10
2009 8
2010 14
2011 16
2012 19
2013 18
2014 14
2015 14
2016 25
2017 32
2018 30
2019 31
2020 28
2021 40
2022 22
2023 23
2024 14
2025 9
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

510 results

Results by year

Filters applied: . Clear all
Page 1
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V. Fakhouri F, et al. Among authors: rondeau e. Blood. 2021 May 6;137(18):2438-2449. doi: 10.1182/blood.2020009280. Blood. 2021. PMID: 33270832 Free article. Clinical Trial.
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Dec;98(6):1621. doi: 10.1016/j.kint.2020.11.001. Kidney Int. 2020. PMID: 33276869 Free article. No abstract available.
Exome-First Strategy in Adult Patients With CKD: A Cohort Study.
Doreille A, Lombardi Y, Dancer M, Lamri R, Testard Q, Vanhoye X, Lebre AS, Garcia H, Rafat C, Ouali N, Luque Y, Izzedine H, Esteve E, Cez A, Petit-Hoang C, François H, Marchal A, Letavernier E, Frémeaux-Bacchi V, Boffa JJ, Rondeau E, Raymond L, Mesnard L. Doreille A, et al. Among authors: rondeau e. Kidney Int Rep. 2022 Dec 17;8(3):596-605. doi: 10.1016/j.ekir.2022.12.007. eCollection 2023 Mar. Kidney Int Rep. 2022. PMID: 36938085 Free PMC article.
Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.
Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, Divard G, Jackson AM, Viglietti D, Giral M, Kamar N, Thaunat O, Morelon E, Delahousse M, Kuypers D, Hertig A, Rondeau E, Bailly E, Eskandary F, Böhmig G, Gupta G, Glotz D, Legendre C, Montgomery RA, Stegall MD, Empana JP, Jouven X, Segev DL, Lefaucheur C. Loupy A, et al. Among authors: rondeau e. BMJ. 2019 Sep 17;366:l4923. doi: 10.1136/bmj.l4923. BMJ. 2019. PMID: 31530561 Free PMC article. Clinical Trial.
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2021 May;99(5):1244. doi: 10.1016/j.kint.2021.03.008. Kidney Int. 2021. PMID: 33892867 Free article. No abstract available.
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum.
Kavanagh D, Ardissino G, Brocklebank V, Bouwmeester RN, Bagga A, Ter Heine R, Johnson S, Licht C, Ma ALT, Noris M, Praga M, Rondeau E, Sinha A, Smith RJH, Sheerin NS, Trimarchi H, Wetzels JFM, Vivarelli M, Van de Kar NCAJ, Greenbaum LA; Forum Participants. Kavanagh D, et al. Among authors: rondeau e. Kidney Int. 2024 Dec;106(6):1038-1050. doi: 10.1016/j.kint.2024.09.012. Epub 2024 Oct 10. Kidney Int. 2024. PMID: 39395628 Free PMC article.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Reuniting philosophy and science to advance cancer research.
Pradeu T, Daignan-Fornier B, Ewald A, Germain PL, Okasha S, Plutynski A, Benzekry S, Bertolaso M, Bissell M, Brown JS, Chin-Yee B, Chin-Yee I, Clevers H, Cognet L, Darrason M, Farge E, Feunteun J, Galon J, Giroux E, Green S, Gross F, Jaulin F, Knight R, Laconi E, Larmonier N, Maley C, Mantovani A, Moreau V, Nassoy P, Rondeau E, Santamaria D, Sawai CM, Seluanov A, Sepich-Poore GD, Sisirak V, Solary E, Yvonnet S, Laplane L. Pradeu T, et al. Among authors: rondeau e. Biol Rev Camb Philos Soc. 2023 Oct;98(5):1668-1686. doi: 10.1111/brv.12971. Epub 2023 May 8. Biol Rev Camb Philos Soc. 2023. PMID: 37157910 Free PMC article.
Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation.
Cremoni M, Teisseyre M, Thaunat O, Fernandez C, Payre C, Moutou A, Zarif H, Brglez V, Albano L, Moal V, Mourad G, Morelon E, Hurault de Ligny B, Zaoui P, Rondeau E, Ouali N, Ronco P, Moulin B, Braun-Parvez L, Durrbach A, Heng AE, Grimbert P, Ducloux D, Blancho G, Merville P, Choukroun G, Le Meur Y, Vigneau C, Mariat C, Rostaing L, Subra JF, Taupin JL, Lambeau G, Esnault V, Sicard A, Seitz-Polski B. Cremoni M, et al. Among authors: rondeau e. Kidney Int Rep. 2024 Sep 23;9(12):3427-3438. doi: 10.1016/j.ekir.2024.09.012. eCollection 2024 Dec. Kidney Int Rep. 2024. PMID: 39698349 Free PMC article.
510 results